Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Priva
Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical ProgramsSyros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal DataNow Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023Syros to Host Conference Call at 8:30 AM ET Today...